Eqis Capital Management Inc. raised its position in Sanofi (NYSE:SNY) by 12.5% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 20,172 shares of the company’s stock after buying an additional 2,245 shares during the period. Eqis Capital Management Inc.’s holdings in Sanofi were worth $966,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also made changes to their positions in SNY. Gradient Investments LLC boosted its position in shares of Sanofi by 15,470.7% in the first quarter. Gradient Investments LLC now owns 6,384 shares of the company’s stock worth $289,000 after buying an additional 6,343 shares in the last quarter. E&G Advisors LP boosted its position in Sanofi by 9.9% in the first quarter. E&G Advisors LP now owns 23,125 shares of the company’s stock worth $1,046,000 after buying an additional 2,075 shares during the period. Quadrant Capital Group LLC boosted its position in Sanofi by 126.0% in the first quarter. Quadrant Capital Group LLC now owns 5,525 shares of the company’s stock worth $242,000 after buying an additional 3,080 shares during the period. Raymond James Trust N.A. boosted its position in Sanofi by 5.5% in the first quarter. Raymond James Trust N.A. now owns 51,614 shares of the company’s stock worth $2,336,000 after buying an additional 2,702 shares during the period. Finally, New England Research & Management Inc. purchased a new position in Sanofi during the first quarter worth about $208,000. Hedge funds and other institutional investors own 9.96% of the company’s stock.
Shares of Sanofi (NYSE:SNY) traded up 0.30% during midday trading on Friday, hitting $47.55. 717,957 shares of the stock were exchanged. Sanofi has a 1-year low of $36.81 and a 1-year high of $50.24. The stock has a market capitalization of $119.42 billion, a price-to-earnings ratio of 11.23 and a beta of 0.88. The firm’s 50 day moving average is $48.05 and its 200-day moving average is $46.06.
Sanofi (NYSE:SNY) last announced its quarterly earnings data on Monday, July 31st. The company reported $0.74 EPS for the quarter, hitting the consensus estimate of $0.74. The business had revenue of $8.66 billion for the quarter, compared to analyst estimates of $8.71 billion. Sanofi had a net margin of 25.89% and a return on equity of 25.34%. The business’s quarterly revenue was down 2.3% on a year-over-year basis. On average, analysts predict that Sanofi will post $3.26 EPS for the current year.
Several research analysts recently weighed in on the stock. Argus boosted their price objective on shares of Sanofi from $50.00 to $55.00 and gave the stock a “buy” rating in a research report on Friday, June 9th. Cowen and Company restated a “market perform” rating and issued a $52.00 price objective (up previously from $46.00) on shares of Sanofi in a research report on Tuesday, August 1st. TheStreet upgraded shares of Sanofi from a “c+” rating to a “b-” rating in a research report on Monday, April 24th. BidaskClub raised shares of Sanofi from a “sell” rating to a “hold” rating in a report on Saturday, August 5th. Finally, Zacks Investment Research lowered shares of Sanofi from a “buy” rating to a “hold” rating in a report on Tuesday, April 25th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and five have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $63.75.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
What are top analysts saying about Sanofi? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Sanofi and related companies.